T1	Participants 65 124	5-year failure-free survival in group III rhabdomyosarcoma:
T2	Participants 352 385	osteosarcoma and Ewing's sarcoma.
T3	Participants 433 473	patients with group III rhabdomyosarcoma
T4	Participants 599 743	444 group III patients who received induction therapy, had response assessed at week 8 by anatomic imaging, and continued with protocol therapy.
T5	Participants 1786 1804	group III patients
